Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ALEMTUZUMAB
- Safety and Efficacy Study of hAESCs Therapy for aGVHD
- Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function
- Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
- Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
- Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
- TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
- Addition of JSP191 (C-kit Antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia
- Preservation and Transfer of HBV Immunity After Allogeneic HSCT for SCD.
- Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial
- PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
- Reduced Intensity Transplantation for Severe Sickle Cell Disease
- Allogeneic Hematopoietic Stem Cell Transplant for People With Primary Immunodeficiency Diseases
- Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
- Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
- Autologous Transplant Targeted Against Crohn's
- Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis
- Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation
- Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
- Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis
- Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
- A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
- T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
- Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
- CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients
- Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease
- Tolerance by Engaging Antigen During Cellular Homeostasis
- Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
- RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS
- Stem Cell Transplant in Patients With Severe Sickle Cell Disease
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
- The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
- Precision Dosing of Alemtuzumab
- Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
- Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in HLA Sensitized Kidney Transplant Recipients
- Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
- Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
- Cyclophosphamide and Alemtuzumab In Lymphoma
- Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
- Islet Transplantation Using PKX-001
- Energy Balance Following Islet Transplantation
- Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
- HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
- Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
- Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
- Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
- Cyclosporine Plus Methotrexate or Alemtuzumab
- Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease
- A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
- High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
- A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
- Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)
- Aralast NP in Islet Transplant
- Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells
- Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
- Treatment of Familiar Lymphohistiocytosis
- Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
- A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
- Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
- Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
- Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
- Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
- Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients
- SCT Plus Immune Therapy in Average Risk AML/MDS
- Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
- Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
- SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
- Role of Everolimus in Highly Sensitized Patients
- Islet Cell Transplant for Type 1 Diabetes
- Stem Cell Transplantation for Sickle Cell Anemia
- Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
- Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus
- CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
- Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)
- Belatacept Early Steroid Withdrawal Trial
- Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
- Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
- Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma
- High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
- Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders
- A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
- Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects
- Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
- A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
- Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment
- Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
- Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
- Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
- Phase IV Observational Study in Chronic Lymphocytic Leukemia
- Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
- Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
- Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
- Alemtuzumab and Rituximab in Aplastic Anemia
- Alemtuzumab for ANCA Associated Refractory Vasculitis
- Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
- Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine
- Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
- Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients
- Advanced MRI Measures of Repair in Alemtuzumab Treated Patients
- Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
- Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment
- Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab
- Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
- Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
- Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
- A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
- Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
- Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
- Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols
- A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
- Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
- Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
- Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study
- Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease
- Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
- Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
- Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
- Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
- A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
- Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
- Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
- Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
- T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
- Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
- Haploidentical PBMC Transplant for Severe Congenital Anemias
- Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)
- Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
- Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
- Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)
- Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
- A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
- Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure
- Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
- Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
- Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
- Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
- Allo-hNHL (FluBuCy)
- Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning
- Allogeneic Transplantation For Severe Osteopetrosis
- Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
- Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
- Alemtuzumab + Rituximab Consolidation in CLL
- Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
- Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
- Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
- Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
- Autologous Stem Cell Transplantation for Crohn's Disease
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation
- Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation
- Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Alemtuzumab and CHOP in T-cell Lymphoma
- A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
- Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis
- Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
- Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia
- Campath Maintenance in Chronic Lymphocytic Leukemia
- Oral Paricalcitol in Kidney Transplant Recipients
- Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders
- Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
- Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
- Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
- T-Reg Cell Kinetics, Stem Cell Transplant, REGALE
- Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
- Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
- A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response
- Belatacept Post Depletional Repopulation to Facilitate Tolerance
- Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
- Oral Valganciclovir Versus Valacyclovir
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
- Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders
- Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
- Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
- Reduced Intensity AlloSCT in(CML) With Persistent Disease
- Non-Myeloablative Allogeneic Stem Cell Transplantation
- CFAR Study in Patients With Chronic Lymphocytic Leukemia
- Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
- Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
- R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia
- Campath in Chronic GVHD
- The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias
- Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia
- Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
- Alemtuzumab and Pentostatin In T-cell Neoplasms
- Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
- The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
- Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia
- Donor Stem Cell Transplantation for Congenital Immunodeficiencies
- Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
- Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
- Stem Cell Transplant in Sickle Cell Disease and Thalassemia
- HSCT for High Risk Inherited Inborn Errors
- T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
- Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
- HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
- Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia
- Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia
- Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia
- Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
- Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
- CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
- Simultaneous Pancreas-kidney Transplantation With Campath Protocol
- Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
- A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion
- Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism
- Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia
- Hematopoietic Stem Cell Support in Vasculitis
- Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
- Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
- CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation
- Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
- Phase 2 Fludarabine, Cytoxan and FCCAM
in Untreated B-Cell Chronic Lymphocytic Leukemia - A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome
- Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
- Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath
- Alemtuzumab to Treat Severe Aplastic Anemia
- Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
- Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation
- Stem Cell Transplant for Immunologic or Histiocytic Disorders
- Stem Cell Transplant for Hemoglobinopathy
- Islet Transplantation Using Campath-1H and Infliximab Induction
- Alemtuzumab Induction in Islet Transplantation
- Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation
- A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
- Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
- Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
- Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
- Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
- Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)
- Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection
- Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
- Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
- Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
- Campath-1H + FK506 and Methylprednisolone for GVHD
- Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
- Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
- Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia
- Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
- Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
- Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
- Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Alemtuzumab to Treat Sporadic Inclusion Body Myositis
- Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
- Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
- Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
- Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
- Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
- Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
- Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
- Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
- Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma
- Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
- Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
- Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
- Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
- Safety and Efficacy of Campath in Nonmyeloablative Transplantation
- Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
- Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
- Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
Clinical trials list
click for details